Shareholder alert: weiss law investigates oyster point pharma, inc.

New york , nov. 7, 2022 /prnewswire/ -- weiss law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of oyster point pharma, inc. ("oyster point" or the "company") (nasdaq: oyst), in connection with the proposed acquisition of the company by viatris inc. (nasdaq: vtrs) via tender offer. under the terms of the merger agreement, the company's shareholders will receive $11.00 in cash for each share of oyster point common stock owned, plus a contingent value right ("cvr") representing the right to receive a potential cash payment of up to $2.00 per share.
VTRS Ratings Summary
VTRS Quant Ranking